News Headline Summary

Johnson & Johnson (JNJ) failed to warn vaginal mesh risk, lawyer tells jury

- First case of 1,800 in vaginal mesh trial.

Update details:

- The trial relates to a vaginal mesh implant in a case brought by a South Dakota woman who blames the product for constant pain and 18 subsequent operations.

Reaction details:

- No immediate reaction in JNJ shares, last trade at USD 72.70 (+0.66%).

Print 17:23, 10 Jan 2013 - US Equities - Source: Newswires